Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
August 02, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
July 26, 2023 08:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the...
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
May 11, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
May 10, 2023 16:05 ET
|
Matinas BioPharma Holdings, Inc.
FDA feedback from Type B meeting reiterated the Agency’s intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial design...
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
May 03, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery...
Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID
April 18, 2023 08:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its...
Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update
March 15, 2023 16:05 ET
|
Matinas BioPharma Holdings, Inc.
Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting...
Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023
March 08, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID
March 02, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its...
Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
January 30, 2023 16:01 ET
|
Matinas BioPharma Holdings, Inc.
2022 Success Has Increased Confidence to Focus LNC Delivery Platform on the Future of Medicine - Delivering Genes Prioritization on Building External Partnerships and an Internal Pipeline Centered...